Fluidigm, OpGen Collaborate
News Jul 14, 2015
Under the terms of the five-year agreement, the firms will develop tests for the identification, screening, and surveillance of multi-drug resistant pathogens built on Fluidigm's Juno instrument for automating SNP genotyping assays and its Biomark real-time endpoint PCR. The firms will cooperate on quality and regulatory compliance and will have the option to extend the agreement for an additional five years.
"With this expanded relationship, OpGen anticipates developing customized solutions for our CLIA lab customers, strategic partners, and testing laboratories globally," OpGen President Kevin Krenitsky said in a statement, noting that the firm's Acuitas MDRO Gene Test and Resistome Test use Fluidigm's microfluidics.
Steve McPhail, Fluidigm's general manager for production genomics, said, that the partners will seek government funding to develop new products, including molecular information analytics, based on each other's technologies.
Gaithersburg, Maryland-based OpGen offers molecular testing and informatics to help healthcare organizations fight drug-resistant pathogens.
SCIEX Announces Joint Venture with Zhenjang Dian Diagnostics in ChinaNews
Leading diagnostics companies combine to address diagnostic and wellness testing in China.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE